How to buy BioNTech (BNTX) shares in Australia
Learn how to easily invest in BioNTech shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
BioNTech's COVID-19 vaccine (co-developed with Pfizer) has made headlines with the announcement of its 90% efficacy rate. But this early data is subject to change and the vaccine must pass rigorous testing by the Therapeutic Goods Administration’s (TGA) before it's approved for use in Australia.
BioNTech SE is a German biotechnology company founded in 2008. BioNTech's COVID-19 vaccine (co-developed with Pfizer) propelled the company into the spotlight in 2020 with the announcement of its 90% efficacy rate. As one of the front runners in the development of a successful global vaccine, BioNTech's share price has since surged more than 600% by June 2021.
How to buy shares in BioNTech
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for BioNTech. Find the share by name or ticker symbol: BNTX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioNTech reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$352.99, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of BioNTech, depending on your broker.
- Check in on your investment. Congratulations, you own a part of BioNTech. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
BioNTech stock price (NASDAQ:BNTX)Use our graph to track the performance of BNTX stocks over time.
BioNTech shares at a glance
|52-week range||US$65.72 - US$464|
|50-day moving average||US$358.614|
|200-day moving average||US$232.7218|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$18.056|
Where to buy BioNTech stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy BioNTech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying BioNTech shares?Before you consider BioNTech, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
BioNTech price performance over time
|1 week (2021-09-21)||-2.31%|
|1 month (2021-08-27)||-6.97%|
|3 months (2021-06-28)||45.98%|
|6 months (2021-03-26)||248.25%|
|1 year (2020-09-28)||401.47%|
Is BioNTech under- or over-valued?
Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioNTech's P/E ratio
BioNTech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, BioNTech shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
BioNTech's PEG ratio
BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0697. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioNTech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$5.6 billion (£4.1 billion).
The EBITDA is a measure of a BioNTech's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||US$7.8 billion|
|Operating margin TTM||71.2%|
|Gross profit TTM||US$-222,037,000|
|Return on assets TTM||68.31%|
|Return on equity TTM||133.85%|
|Market capitalisation||US$80.9 billion|
TTM: trailing 12 months
Shorting BioNTech shares
There are currently 2.1 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 2.4% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.
BioNTech's "short interest ratio" (SIR)
BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 6.2 million). BioNTech's SIR currently stands at 0.34. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 340 shares are currently held short.
However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 10 shares are currently held short) or 0.0273% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.
Find out more about how you can short BioNTech stock.
BioNTech share dividends
We're not expecting BioNTech to pay a dividend over the next 12 months.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech in the news
CDC director on Covid booster shots: ‘I am not at all concerned about supply’
Why BioNTech Shares Are Falling
Stocks making the biggest moves midday: Best Buy, Altice, Occidental, Moderna and more
Frequently asked questions
More guides on Finder
How to buy Evergrande shares from Australia
Steps to owning and managing China Evergrande Group shares from Australia.
How to buy Incannex Healthcare (IHL) shares
Steps to owning and managing Incannex Healthcare from Australia.
How to buy The Scotts Miracle-Gro Company (SMG) shares in Australia
Steps to owning and managing Scotts Miracle Go shares from Australia.
How to buy Rubicon Water (RWL) shares
Steps to owning and managing Rubicon Water shares.
How to buy Endeavour Group (EDV) shares
Steps to owning and managing Endeavour Group Limited shares from Australia.
How to buy Betashares Legg Mason Emerging Markets Fund Managed Fund units | A$6.99
Steps to owning and managing BetaShares Legg Mason Emerging Markets Fund (Managed Fund) ETF units.
How to buy Einvest Future Impact Small Caps Fund Managed Fund units | A$6.03
Steps to owning and managing eInvest Future Impact Small Caps Fund (Managed Fund) ETF units.
How to buy Vaneck Vectors Msci International Value Etf units | A$22.42
Steps to owning and managing VanEck Vectors MSCI International Value ETF units.
How to buy VanEck MSCI International Small Companies Quality ETF units | A$23.55
Steps to owning and managing VanEck Vectors MSCI International Small Companies Quality ETF units
How to buy The Trustee for Montaka Global Extension Fund Quoted Managed Hedge Fund units | A$4.05
Steps to owning and managing Montaka Global Extension Fund (Quoted Managed Hedge Fund) ETF units
Ask an Expert